Zynerba is conducting clinical studies of Zygel™ in a number of patients with neuropsychiatric conditions in the U.S., Australia, New Zealand and Europe, including the UK. Zygel is an investigational treatment. This means that it is not approved by government regulatory bodies, including the U.S. Food and Drug Administration (FDA).
FXS RECONNECT Trial – now enrolling
RECONNECT (Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome): Enrollment Ongoing
For more information regarding enrollment in RECONNECT, please see:
22q INSPIRE Trial – complete
INSPIRE (Assessing the Impact of Zygel [Transdermal Cannabidiol Gel] on Pediatric Behavioral and Emotional Symptoms of 22q11.2 Deletion Syndrome). For more details click here.
Plan to initiate a Phase 3 program after FDA discussions and RECONNECT (FXS) topline results.
Read more about Zynerba’s clinical pipeline here.